Table 2.
Disease and scale data of FM patients
| Characteristics | Fibromyalgia patients N = 34 |
|---|---|
| Complaint duration (Months)** | 72 (1–360) |
| Diagnosis Duration (Months)** | 24 (1–240) |
| Drugs, n (%) | |
| None | 19 (55.9) |
| Duloxetine | 8 (23.5) |
| Duloxetine + Pregabalin | 3 (8.8) |
| Pregabalin | 3 (8.8) |
| Amitriptyline | 1 (2.9) |
| FM-WPI** | 17 (6–19) |
| FM-SSS** | 10 (2–13) |
| Sleep- VAS** | 6 (1–9) |
| Fatique-VAS** | 8 (4–9) |
| Pain-VAS** | 8 (3–9) |
| FIQ** | 66,97 (29,19–87,8) |
| FIQ Cut Off, n (%) | |
| < 50 | 9 (26.5%) |
| ≥ 50 | 25 (73.5%) |
| CSI total score* | 50 ± 16 |
| CS severity level, n (%) | |
| Subclinic | 3 (8,8) |
| Mild | 7 (20,6) |
| Moderate | 6 (17,6) |
| Severe | 9 (26,5) |
| Extreme | 9 (26,5) |
Abbreviation: CS: Central sensitization, CSI: Central sensitization inventory, FIQ: Fibromyalgia impact questionnaire, SSS: Symptom severity, VAS: visual analogue scale; WPI: widespread pain index, n: number of participants; SD: Standart deviation
** Median (minimum-maximum), * Mean ± SD